Floatz logo

(18F)FPPRGD2

Recurrent Lip and Oral Cavity Cancer

Sanjiv Sam Gambhirprotein_peptidePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Recurrent Lip and Oral Cavity Cancer cohort.

Asset / SponsorPhaseRating
Nivolumab
National Cancer Institute (NCI)
Phase 2B
CIS-DIAMMINEDICHLOROPLATINUM II
Loren Mell, MD
Phase 2B
Pembrolizumab
Loren Mell, MD
Phase 2CCC
FLUDEOXYGLUCOSE
Sanjiv Sam Gambhir
Phase 1/2CCC
ANTI-HER2 ANTIBODY-DRUG CONJUGATE A166
Klus Pharma Inc.
Phase 1/2CCC

View all 21 →

Same molecule, other indications

(18F)FPPRGD2 is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
gliosarcomaDormant
CCC
Indicative ·
52 / 100
View asset →
adult glioblastomaDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →